Investors
Building the infrastructure for a more liquid market in surplus chemicals.
CURRENTLY RAISING
InCycling is currently raising its seed round.
We are actively speaking with investors who share our ambition to build the infrastructure for a more efficient and circular market for surplus chemicals. If you are interested in learning more about InCycling and our next phase of growth, we would be pleased to start a confidential conversation.
Market Opportunity
A large, fragmented market with room for better recovery
The global chemical industry generates more than €5 trillion in annual revenue. Across the sector, surplus inventory can arise from forecast changes, specification updates, production planning, and expiry constraints. Much of this material is difficult to remarket efficiently because information, buyer access, and compliance processes remain fragmented.
InCycling is building the infrastructure to make more of this inventory visible, assessable, and tradable.
€5.1T
estimated size of the global chemical industry
€26B
amount of annual reusable surplus value being destroyed
Market figures are calculations based on publicly available market information.
Business Model
Planned revenue from transactions, software, and services
InCycling's planned revenue model combines transaction fees on completed deals, recurring software fees for connected enterprise sites, and optional service revenue from logistics, certification, and compliance support. Revenue mix, pricing, and margins remain subject to customer validation and commercial rollout.
Early Enterprise Validation
Validation with publicly listed industrial companies.
We are already working with several publicly listed companies to validate our solution in real industrial environments.
300+ trader profiles in our network
Market-intelligence register in development
“What Karym and Sascha are building with InCycling is exactly the kind of pragmatic innovation supply chains need. It turns waste into value while supporting sustainability and cost-efficiency goals. It’s a rare win on all fronts.”
Senior VP Pharmaceutical Supply Chain, Bayer AG
Scaling Strategy
From semi-automated validation to scalable infrastructure.
InCycling's scaling path starts with direct, service-led execution and turns the knowledge created through each opportunity into structured data and repeatable workflows.
Intended scaling path
- Stage 01Today
Semi-automated validation
Assess opportunities through a semi-automated process using proprietary AI algorithms.
- Stage 02In development
Structured market intelligence
Build a growing register of traders, requirements, applications and regulatory information.
- Stage 03Next
Data-driven matching
Turn structured intelligence into a more repeatable matching process.
- Stage 04Long-term scale
Broader distribution and expansion
Extend the infrastructure across categories, enterprise sites, markets and distribution channels.
What compounds
Funding Status
Early stage. Funding plans linked to milestones.
InCycling is currently raising a seed round. Current funding sources and requirements are shared with investors on a confidential and up-to-date basis.
INVEST – Zuschuss für Wagniskapital
Team
Built by people with direct industry experience
Founded by former Bayer, Roche & West Pharma leaders with experience in regulated enterprise software, pharmaceutical procurement, and global supply chains.
Interested in joining our seed round?
Get in touch to start a confidential conversation with the founding team.